Skip to main content

Table 2 Univariate and multivariate Cox proportional hazards regression analysis for OS

From: Co-expression of SOX2 and HR-HPV RISH predicts poor prognosis in small cell neuroendocrine carcinoma of the uterine cervix

Variables Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Age (years) (< 44 vs. ≥44) 1.253 (0.632–2.482) 0.518   
HPV DNA (pg/ml) (< 1 vs. ≥1) 0.240 (0.071–0.813) 0.022   
FIGO stage (≤IIA vs. ≥IIB) 2.373 (0.914–6.158) 0.076   
Pathological type (SCNEC -alone vs. SCNEC -mix) 1.448 (0.661–3.174) 0.355   
Pre-operative Chemotherapy (No vs. Yes) 1.148 (0.721–2.787) 0.312   
Post-operative Chemotherapy (No vs. Yes) 0.514 (0.122–2.161) 0.364   
Post-operative Radiotherapy (No vs. Yes) 1.558 (0.726–3.342) 0.255   
Tumor size (cm) (< 2 vs. 2–4 vs. ≥4) 1.528 (0. 890–2.624) 0.124   
Stromal invasion (<  1/2 vs. ≥1/2) 2.481 (1.026–5.997) 0.044 6.377 (1.397–29.118) 0.017
Endometrial invasion (No vs. Yes) 1.841 (0.711–4.769) 0.209   
Parametrium invasion (No vs. Yes) 2.946 (1.276–6.802) 0.011 4.663 (1.496–14.533) 0.008
CIN (No vs. Yes) 0.667 (0.235–1.898) 0.448   
LNM (No vs. Yes) 1.697 (0.865–3.326) 0.124   
Nerve invasion (No vs. Yes) 3.630 (1.814–7.264) 0.000 4.044 (1.514–10.804) 0.005
LVI (No vs. Yes) 2.150 (0.964–4.797) 0.061   
N-marker (≤2+ vs. > 2+) 1.777 (0.542–5.829) 0.343   
MMR (pMMR vs. dMMR) 0.039 (0.001–2.816) 0.138   
Ki67 (< 60 vs. ≥60%) 1.485 (0.522–4.223) 0.458   
SOX2 (Low vs. High) 2.658 (1.154–6.125) 0.022 4.437 (1.276–15.428) 0.019
P16INK4A (− vs. +) 2.646 (0.806–8.690) 0.109   
HR-HPV RISH (− vs. +) 3.195 (0.961–10.625) 0.048 5.160 (1.098–24.254) 0.038
SOX2/ P16INK4A (AI vs. AII vs. AIII) 2.457 (1.267–4.766) 0.008 1.593 (0.481–5.274) 0.446
SOX2/ HR-HPV RISH (BI vs. BII vs. BIII) 3.462 (1.655–7.242) 0.001 3.597 (1.085–11.928) 0.036
  1. CIN Cervical Intraepithelial Neoplasia, LNM Lymph Node Metastasis, LVI Lymphatic Vessel Invasion, N-marker Neuroendocrine-marker, MMR Mismatch Repair, AI SOX2Low/P16INK4A-; AII: SOX2High/P16INK4A- or SOX2Low/P16INK4A+; AIII: SOX2High/P16INK4A+; BI: SOX2Low/HR-HPV RISH-; BII: SOX2High/HR-HPV RISH- or SOX2Low/HR-HPV RISH+; BIII: SOX2High/HR-HPV RISH+